To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
NCT ID: NCT04894591
Last Updated: 2025-06-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
272 participants
OBSERVATIONAL
2021-06-28
2025-05-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection
NCT06021483
Non-small Cell Lung Cancer Study US75 (Z-PACT)
NCT00086268
AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer
NCT00528645
Immunotherapy as Second-line in Patient With Small Cell Lung Cancer
NCT03059667
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
NCT07226999
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zepzelca
Zepzelca is administered by intravenous infusion over 60 minutes every 21 days. Date, dose prescribed and received will be collected at each Zepzelca infusion.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Decision to initiate treatment with Zepzelca was made as per investigator's routine treatment practice prior to enrollment in the study.
3. Patient, or a legally acceptable representative, signed the informed consent before any study-related activities are undertaken.
4. Patients initiating Zepzelca treatment in second-line.
5. Patients who are sensitive to platinum-based chemotherapy with CTFI≥180 days. The CTFI is defined as the length of time from last platinum dose to time of relapse or disease progression.
6. Eastern Cooperative Oncology Group performance status (ECOG) ≤1
Exclusion Criteria
2. Patient who received more than 2 cycles of Zepzelca treatment in their current treatment schedule.
3. Patient received treatment with any investigational agent within 30 days prior to first Zepzelca infusion or plans to use another investigational agent while receiving Zepzelca.
4. Known CNS involvement prior to Zepzelca treatment.
5. Patients who were treated with Zepzelca in later lines rather than in second-line treatment
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jazz Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clearview Cancer Institute
Huntsville, Alabama, United States
Eastern Connecticut Hematology and Oncology
Norwich, Connecticut, United States
ASCLEPES Research Centers
Brooksville, Florida, United States
Woodlands Medical Specialists - Woodlands Center For Specialized Medicine
Pensacola, Florida, United States
Mid-Illinois Hematology & Oncology Associates
Normal, Illinois, United States
Goshen Health Center for Cancer Care
Goshen, Indiana, United States
Siouxland Regional Cancer Center dba June E. Nylen Cancer Center
Sioux City, Iowa, United States
Stormont-Vail Cancer Center-Stormont-Vail Healthcare - Cotton-O'Neil Cancer Center
Topeka, Kansas, United States
Cancer Center of Kansas
Wichita, Kansas, United States
Baptist Health Lexington
Lexington, Kentucky, United States
Pikeville Medical Center - Leonard Lawson Cancer Center
Pikeville, Kentucky, United States
West Jefferson Cancer Center
Marrero, Louisiana, United States
MMCORC - HealthPartners Institute
Saint Louis Park, Minnesota, United States
Singing River Health System
Pascagoula, Mississippi, United States
Central Care Cancer Center
Bolivar, Missouri, United States
Benefis Medical Group
Great Falls, Montana, United States
Regional Cancer Care Associates LLC (RCCA)
Hackensack, New Jersey, United States
Center for Clinical Research-Rochester General Hospital
Rochester, New York, United States
Montefiore Medical Center (MMC) - Montefiore Medical Park (MMP)
The Bronx, New York, United States
University of North Carolina NASH Cancer Center
Rocky Mount, North Carolina, United States
Trinity Cancercare Center
Minot, North Dakota, United States
Gabrail Cancer Center Research
Canton, Ohio, United States
Tri-County Hematology & Oncology Associates, Inc
Massillon, Ohio, United States
Lankenau Institute for Medical Research
Wynnewood, Pennsylvania, United States
Charleston Hematology Oncology Associates, PA
Charleston, South Carolina, United States
Carolina Blood & Cancer Care Associates
Rock Hill, South Carolina, United States
Lexington Oncology Associates
West Columbia, South Carolina, United States
Monument Health Cancer Care Institute
Rapid City, South Dakota, United States
Baptist Cancer Center
Memphis, Tennessee, United States
Baylor Scott & White Medical Center - Temple
Temple, Texas, United States
Tranquil Clinical Research
Webster, Texas, United States
ThedaCare Regional Cancer Center
Appleton, Wisconsin, United States
Cape Breton Cancer Centre
Sydney, Nova Scotia, Canada
Southlake Regional Health Centre (York County Hospital)
Newmarket, Ontario, Canada
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Centre Integre Universitaire de Sante et de Services Sociaux du Saguenay-Lac-Saint-Jean
Chicoutimi, Quebec, Canada
Centre integre de sante et de services sociaux de Chaudiere-Appalaches
Lévis, Quebec, Canada
Centre integre de Sante Et De Services Sociaux du Bas-Saint-Laurent Hopital regional de Rimousk
Rimouski, Quebec, Canada
Universite Laval - Institut Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ) (Hopital Laval)
Sainte-Foy, Quebec, Canada
CIUSSS de L'Estrie - CHUS - Hopital Fleurimont
Sherbrooke, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JZP712-402
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.